compared with none in the treatment group (24% vs 0%, respectively, P = 0.01 by log-rank). The results indicate that in recipients of HBsAg-positive marrow in HSCT, HBV-related hepatitis and ...

Detailed chart review was performed to identify all patients who were administered HBV vaccine within 180 days prior to HBsAg testing and also to ascertain likely cause of weakly positive ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, ...